PHAR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	4 488.00
Average Volume	2 674.00
Market Cap	723.47M
EPS	€0 ( 2024-03-14 )
Next earnings date	( €0.0100 ) 2024-05-09
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-65.31
ATR14	€0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2004-05-27	Camden Partners Strategic Fund Ii A Lp	Buy	5 000	Stock Option (right to buy)

INSIDER POWER
0.00
Last 1 transactions
Buy: 5 000 \| Sell: 0

Pharming Group N.V. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pharming Group N.V. Financials

Annual	2023
Revenue:	€245.32M
Gross Profit:	€220.10M (89.72 %)
EPS:	€0

Q4	2023
Revenue:	€81.87M
Gross Profit:	€67.09M (81.95 %)
EPS:	€-0.0406

Q3	2023
Revenue:	€66.66M
Gross Profit:	€58.37M (87.56 %)
EPS:	€0.0525

Q2	2023
Revenue:	€54.90M
Gross Profit:	€49.17M (89.57 %)
EPS:	€0.0200

Financial Reports:

No articles found.

Pharming Group N.V.

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.